Cargando…

Comparison of plasma and CSF biomarkers in predicting cognitive decline

OBJECTIVES: Concentrations of amyloid‐β peptides (Aβ42/Aβ40) and neurofilament light (NfL) can be measured in plasma or cerebrospinal fluid (CSF) and are associated with Alzheimer’s disease brain pathology and cognitive impairment. This study directly compared plasma and CSF measures of Aβ42/Aβ40 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aschenbrenner, Andrew J., Li, Yan, Henson, Rachel L., Volluz, Katherine, Hassenstab, Jason, Verghese, Philip, West, Tim, Meyer, Matthew R., Kirmess, Kristopher M., Fagan, Anne M., Xiong, Chengjie, Holtzman, David, Morris, John C., Bateman, Randall J., Schindler, Suzanne E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639639/ https://www.ncbi.nlm.nih.gov/pubmed/36183195 http://dx.doi.org/10.1002/acn3.51670

Ejemplares similares

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Diurnal oscillation of CSF Aβ and other AD biomarkers
por: Lucey, Brendan P., et al.
Publicado: (2017)

Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light
por: Schindler, Suzanne E., et al.
Publicado: (2022)

Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2018)

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease
por: Barthélemy, Nicolas R., et al.
Publicado: (2023)

Two-period linear mixed effects models to analyze clinical trials with run-in data when the primary outcome is continuous: Applications to Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2019)

African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
por: Schindler, Suzanne E., et al.
Publicado: (2021)

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis
por: West, Tim, et al.
Publicado: (2021)

Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer’s disease
por: Salvadó, Gemma, et al.
Publicado: (2023)

CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
por: Strain, Jeremy F., et al.
Publicado: (2022)

CSF sTREM2: marking the tipping point between preclinical AD and dementia?
por: Schindler, Suzanne E, et al.
Publicado: (2016)

Independent study demonstrates amyloid probability score accurately indicates amyloid pathology
por: Fogelman, Ilana, et al.
Publicado: (2023)

Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease
por: Brier, Matthew R., et al.
Publicado: (2016)

Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis
por: Craig-Schapiro, Rebecca, et al.
Publicado: (2011)

Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD
por: Schindler, Suzanne Elizabeth, et al.
Publicado: (2015)

Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease
por: Hassenstab, Jason, et al.
Publicado: (2021)

Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study
por: Morenas-Rodríguez, Estrella, et al.
Publicado: (2022)

A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects
por: Ghosal, Kaushik, et al.
Publicado: (2016)

Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease
por: Llibre-Guerra, Jorge J., et al.
Publicado: (2019)

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline
por: Suárez‐Calvet, Marc, et al.
Publicado: (2018)

Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
por: Elbert, Donald L., et al.
Publicado: (2022)

A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease
por: Budelier, Melissa M., et al.
Publicado: (2022)

Relationships between big‐five personality factors and Alzheimer's disease pathology in autosomal dominant Alzheimer's disease
por: Aschenbrenner, Andrew J., et al.
Publicado: (2020)

Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease
por: Wang, Qing, et al.
Publicado: (2022)

Proportional constrained longitudinal data analysis models for clinical trials in sporadic Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
por: Hu, Yan, et al.
Publicado: (2022)

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease
por: Horie, Kanta, et al.
Publicado: (2023)

Preclinical Alzheimer's disease and longitudinal driving decline
por: Roe, Catherine M., et al.
Publicado: (2016)

Sex-Specific Patterns of Body Mass Index Relationship with White Matter Connectivity
por: Rahmani, Farzaneh, et al.
Publicado: (2022)

Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study
por: Millar, Peter R, et al.
Publicado: (2023)

Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease
por: Sutphen, Courtney L., et al.
Publicado: (2018)

The informed road map to prevention of Alzheimer Disease: A call to arms
por: McDade, Eric, et al.
Publicado: (2021)

The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial
por: Abdullah, Laila, et al.
Publicado: (2020)

Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation
por: Achariyar, Thiyagaragan M., et al.
Publicado: (2016)

Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation
por: Achariyar, Thiyagaragan M., et al.
Publicado: (2017)

Insulin resistance is related to cognitive decline but not change in CSF biomarkers of Alzheimer's disease in non‐demented adults
por: Ennis, Gilda E., et al.
Publicado: (2021)

BMI1 is associated with CSF amyloid-β and rates of cognitive decline in Alzheimer’s disease
por: Kim, Jun Pyo, et al.
Publicado: (2021)

Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation
por: Perrin, Richard J., et al.
Publicado: (2013)

Falls: a marker of preclinical Alzheimer disease: a cohort study protocol
por: Bollinger, Rebecca M, et al.
Publicado: (2021)

Asthma amplifies dementia risk: Evidence from CSF biomarkers and cognitive decline
por: Nair, Ajay Kumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rn7odl196e3ah79nfatqp55pe5